

IN THE CLAIMS

1. (Withdrawn) A method of modulating an immune system response to an antigen in a mammal, said method comprising administering to said mammal a particle-free therapeutic comprising a hyaluronic acid polymer analogue covalently linked to at least one peptide that comprises a T cell epitope recognized by an MHC molecule of said mammal, wherein said T cell epitope is defined by a sequence of at least about eight amino acids of said antigen.
2. (Withdrawn) The method of Claim 1 wherein said T cell epitope is recognized by an MHC Class I molecule and by a CD8⁺ T cell of said mammal.
3. (Withdrawn) The method of Claim 1 wherein said T cell epitope is recognized by an MHC Class II molecule and by a CD4⁺ T cell of said mammal.
4. (Withdrawn) The method of Claim 2 wherein said immune system response comprises a cytotoxic T lymphocyte that recognizes said antigen.
5. (Withdrawn) The method of Claim 2 wherein said immune system response comprises a CD4⁺ T cell that recognizes said antigen.
6. (Withdrawn) The method of Claim 1 wherein said immune system response comprises an antibody that recognizes said antigen.
7. (Withdrawn) The method of Claim 1 wherein said immune system response to said antigen is increased after administration of said conjugate.
8. (Withdrawn) The method of Claim 7 wherein said antigen is an antigen of a pathogenic agent or a tumor cell.
9. (Withdrawn) The method of Claim 3 wherein said immune system response to said antigen is decreased after administration of said conjugate.
10. (Withdrawn) The method of Claim 9 wherein said antigen is an antigen of a tissue or organ transplanted to said mammal.

11. (Withdrawn) The method of Claim 1 wherein said step of administering further comprises administering a plurality of conjugates each comprising at least one peptide that comprises a T cell epitope recognizable by an MCH molecule linked to a hyaluronic acid polymer analogue wherein the peptides of at least two such conjugates are different.

12. (Withdrawn) A method of improving MHC presentation of a T cell epitope of an antigen in a mammal comprising administering to said mammal a conjugate comprising particle-free hyaluronic acid polymer analogue covalently linked to a peptide that comprises a T cell epitope recognized by an MHC molecule of said mammal, wherein said T cell epitope is defined by a sequence of at least about eight amino acids of said antigen.

13. (Currently Amended) A pharmaceutical composition for administration to a mammal for improving MHC presentation of a T cell epitope of an antigen in said mammal, said composition comprising a conjugate comprising a particle-free hyaluronic acid polymer analogue having a molecular weight of at least 50,000 daltons covalently linked to a ~~peptide that comprises polypeptide consisting of~~ a T cell epitope, wherein the T cell epitope is recognized by an MHC molecule of said mammal, ~~wherein said T cell epitope is defined by a sequence of at least about eight amino acids of said antigen.~~

14. (Currently Amended) A composition of matter comprising a particle-free hyaluronic acid polymer analogue having a molecular weight of at least 50,000 daltons covalently linked to at least one ~~peptide comprising a~~ polypeptide consisting of a T cell epitope, wherein the T cell epitope is recognized by an MHC molecule of a mammal.

15. (New) The composition of Claim 13, wherein the hyaluronic acid polymer analogue is conjugated to a plurality of polypeptides each consisting of a different T cell epitope, wherein each of the different T cell epitopes is recognized by an MHC molecule of the mammal.

16. (New) The composition of Claim 13, wherein the hyaluronic acid polymer analogue is conjugated to a second polypeptide consisting of a B cell epitope, wherein the B cell epitope is recognized by an MHC molecule of the mammal.

17. (New) The composition of Claim 13, wherein the T cell epitope is recognized by an MHC Class I molecule of the mammal.

18. (New) The composition of Claim 13, wherein the T cell epitope is recognized by an MHC Class II molecule of the mammal.

19. (New) The composition of Claim 13, wherein the hyaluronic acid polymer analogue has a molecular weight of at least 250,000 daltons.

20. (New) The composition of Claim 13, wherein the hyaluronic acid polymer analogue has a molecular weight of at least 500,000 daltons.

21. (New) The composition of Claim 13, wherein the hyaluronic acid polymer analogue has a molecular weight of at least 750,000 daltons.